about
Virus-free induction of pluripotency and subsequent excision of reprogramming factorsEfficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitroSS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic ModifierpiggyBac transposition reprograms fibroblasts to induced pluripotent stem cellsRetro-recombination screening of a mouse embryonic stem cell genomic library.Orpheus recombination : a comprehensive bacteriophage system for murine targeting vector construction by transplacement.Transgene-free production of pluripotent stem cells using piggyBac transposons.Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming.An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming.Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.KLF4 N-terminal variance modulates induced reprogramming to pluripotencyMutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.Reprogramming Roadblocks Are System Dependent.Cellular context-dependent consequences of Apc mutations on gene regulation and cellular behavior.New strategies to generate induced pluripotent stem cells.Nuclease-mediated genome editing: At the front-line of functional genomics technology.An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma DevelopmentInducible Transgene Expression in Human iPS Cells Using Versatile All-in-One piggyBac Transposons.Transient maternal IL-6 mediates long-lasting changes in neural stem cell pools by deregulating an endogenous self-renewal pathway.Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.Highly efficient site-specific transgenesis in cancer cell lines.Induced pluripotent stem cell lines derived from equine fibroblasts.Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells.Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives.Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.Synthetic lateral inhibition governs cell-type bifurcation with robust ratios.Report on the Conference on Transposition and Genome Engineering 2015 (TGE 2015): advancing cutting-edge genomics technology in the ancient city of Nara.Beta-cell replacement strategies for diabetes.The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.The piggyBac Transposon as a Platform Technology for Somatic Cell Reprogramming Studies in Mouse.Evolutionarily Distinctive Transcriptional and Signaling Programs Drive Human Germ Cell Lineage Specification from Pluripotent Stem Cells.iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease.Efficient TALEN construction and evaluation methods for human cell and animal applications.Microhomology-assisted scarless genome editing in human iPSCs.Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs.Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency.Directed Myogenic Differentiation of Human Induced Pluripotent Stem Cells.In vivo reprogramming drives Kras-induced cancer development.PhiC31 integrase facilitates genetic approaches combining multiple recombinasesPreview. Inhibition of Tgf-beta signaling improves mouse fibroblast reprogramming
P50
Q24644686-3AB5FA3B-BF9D-4A6A-AE55-674FED5BCD1EQ27324593-7D0AD24A-4ADA-4BE4-B06F-73FFD0EDB83FQ28550973-31E3C182-21C4-43A5-9EDF-0F1941936A92Q29619409-3B3BA38A-58A5-4A6E-AE9C-C67201980F60Q30855727-6744B4E8-02AC-47C9-9642-D39307F606BAQ33325959-A8D702EA-7451-4B6F-8A7E-A1EAD7E17EC2Q34028014-25506264-5AD9-4143-97F0-8F2ECF321C7FQ34125369-8E58BC33-0112-4D90-8AF3-1CADA0707B50Q34216981-97A999C1-689C-4621-9B12-0B21BF6BF00DQ34404346-78F3A93E-98EC-4E81-9D52-3AB3FF703C32Q35453993-67CD2D2D-1C35-49E9-9057-7BCB610A5F07Q35687860-6EB66197-9795-4B42-A12A-8CCC56309E71Q36201012-7BAE3296-59AA-4F9F-A010-4F230BC010ADQ37612518-995292BC-34FC-4537-83D0-6727E9C4488CQ37616860-224CB38F-521C-42A2-9C05-A98807E571B7Q38175498-53239F8C-5702-4AF0-9542-7507B76DB0F5Q38784600-F9EE27D3-774F-4800-904B-E35B8C974F12Q38869452-E536858B-4897-43C8-AF95-4C7C576E97D5Q39065517-3130292E-661A-418D-973A-4170BCEB0196Q39140489-AC24350B-F5DC-4792-BC60-E787EF930A3FQ39227915-B49699B6-A24A-4F6A-802E-98267E2CECE2Q39586738-C92105F5-CABE-4D3D-985F-C5E3E2F6B480Q40720742-4D75ED15-F696-4371-BA7F-2D253AFF041CQ41019331-E158E1B2-8A5D-420C-984D-4F833095C85AQ41511257-9EC750D7-77C5-4883-877C-7E84EC94DA14Q42172472-DA734BA8-B79B-4D76-8946-1A94917564E3Q47322586-490D6CF7-2DAD-4BFC-914B-CC78C865D2D2Q47596092-9D0E05C2-10D4-4C16-B75D-95B19E1E4CE9Q47714809-DC898851-7BC0-47C8-B728-AB15AE1E2C4BQ48663246-825E7594-048A-453D-9E32-0CB7DEC157D1Q49555360-160C0C73-00E9-4A8E-8A9A-1B2AA06D6E57Q49793536-4FFD0A82-0B0F-499F-A4D9-0974AC32A697Q51263172-88B4996B-51D4-43D0-A842-A01C234E4BABQ52430597-5CC1CF6C-D9B6-48DC-9E52-A7B017A571E5Q52719972-DBBDFF3A-36A2-4D3F-B30F-030DD6E2AF6FQ52873719-BF9D5CAF-6446-456B-8A69-1241EBB79E62Q53506908-8ADF2C3F-41B1-4E2C-AC27-F563F962AAEAQ55252335-BADBBA1D-1C35-4032-8E06-FA67E830A3CAQ83029978-FBF5C45D-579D-4EE6-AFF3-DFE434B7F98CQ84863657-748EE332-1B2C-4A8E-ADC9-37D9B55AD9EA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Knut Woltjen
@ast
Knut Woltjen
@en
Knut Woltjen
@es
Knut Woltjen
@nl
Knut Woltjen
@sl
type
label
Knut Woltjen
@ast
Knut Woltjen
@en
Knut Woltjen
@es
Knut Woltjen
@nl
Knut Woltjen
@sl
prefLabel
Knut Woltjen
@ast
Knut Woltjen
@en
Knut Woltjen
@es
Knut Woltjen
@nl
Knut Woltjen
@sl
P106
P21
P31
P496
0000-0003-2293-1183